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1. Introduction 
Neoplasms of the central nervous system (CNS) constitute a group of tumors that are 
heterogeneous in epidemiology, biological behavior, genetic alterations, histological type, 
tumor location, pattern of spread, clinical presentation, natural history, age of occurrence, 
and prognosis (Behin et al., 2003; Louis, 2006; Stroher et al., 2000). According to the 2010 
Surveillance Epidemiology and End Results [SEER] data, there were approximately 22,020 
deaths from cancers of the brain and nervous system in the U.S. As reported by Binder et al., 
(2003) and Wrensch et al., (2002), some 7 to 16 cases of primary CNS tumors per 100,000 
person-years are diagnosed in adults; approximately 50% of these cases are metastatic 
tumors, according to Hill et al. 1999.   
CNS tumors are the third leading cause of cancer deaths in middle-aged adults, the second 
most common cause of death in children, and the most common solid tumor in children 
(Giles, 1995; Heuer et al., 2007). The incidence of CNS tumors in children and adolescents is 
approximately 2.7 cases per 100,000 patients per year. This figure accounts for 16% of the 
neoplasms within this group, making CNS tumors the second most frequent type of cancer 
(after leukemia) in young patients (20 years old and younger). The mortality rate observed 
with CNS tumors is one of the highest among childhood cancers. Diagnosis and treatment 
improvements, however, has contributed to the survival of these patients (Potter et al., 
1998). 
Epidemiological studies have shown a slight increase in the incidence of CNS tumors during 
the 1980s and 1990s in children and the elderly (Fisher et al. 2007; Swensen & Bushouse 
1998). The apparent increase in the number of cases of CNS cancers is directly linked to the 
implementation of high-resolution neuroimaging tools, such as Magnetic Resonance 
Imaging (MRI) and Computed Tomography (CT), which have impacted the clinical 
diagnosis of neurological diseases (Cristensen et al., 2003; Fisher et al., 2007). Another 
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important cause for the apparent increase in the incidence of brain tumors is the recent 
inclusion of low-grade neoplasms, which were not previously counted in the population-
based registries (Linet et al., 1999). 
Brain tumors have different incidence rates in different populations, with the highest rates 
in developed countries. Some  factors have influenced the increased incidence in these 
countries, such as the  increased accessibility of medical care and the implementation of 
cutting-edge technologies in health.However, cultural influences and ethnic or geographical 
differences cannot be disregarded as risk factors (Davis, 2007; Ohgaki & Kleihues, 2005). The 
incidence of brain tumors in Japan, for example, is less than half that of the northern 
European countries. In the U.S., neuroepithelial tumors are found more frequently in 
Caucasians than in blacks, Hispanics and Asians (SEER, 2010; Wrensch et al., 2002). 
The etiologic factors of CNS tumors are not well established, and several studies have 
sought to elucidate the risk factors for these cancers. Some of the possible factors are shown 
in Table 1. Among the numerous associations that have been studied, the ones that 
definitely cause primary CNS tumors are the hereditary syndromes (tuberous sclerosis and 
neurofibromatosis Types 1 and 2) and ionizing radiation used for therapeutic purposes 
(Davis, 2007; Guney et al. 2001; Skalr, 2002) 
 
Hereditary syndromes** 
Family history of brain tumors 
Constitutive polymorphisms  
Lymphocyte mutagen sensitivity  
Prior cancers 
Infectious agents or immunological response 
Allergies 
Head trauma 
Epilepsy, seizures, or convulsions 
Drugs and medications 
Diet and vitamins  
Tobacco smoke exposure 
Alcohol 
Hair dyes and sprays 
Traffic-related air pollution 
Occupational and industrial exposures 
Ionizing radiation**  
Cellular telephones 
Other radio frequency exposures 
Power frequency electromagnetic fields 
Table 1. Factors that have been studied in relation to the risk of primary tumors of the 
neuroepithelial tissue or meninges (adapted from Wrensh et al., 2002). **These factors have 
been shown to cause primary brain tumors.  
www.intechopen.com
The Role of Matrix Metalloproteinases and 
Tissue Inhibitors of Metalloproteinases in the Progression of Astrocytomas 595 
The anatomical and pathological classifications of clinical brain tumors are complex and 
controversial, especially with regard to mixed tumors. As a result, the histological 
classification of brain tumors has been subject to constant review from the first attempt at 
histological classification proposed by Bailey & Cushing until today (Louis et al. 2007; 
Wrensh et al., 2002). 
The histological classification of brain tumors currently adopted by the World Health 
Organization (WHO) divides these entities according to the predominant cell type in the 
lesions. This classification extends the concept of the degree of malignancy by incorporating 
data from phenotypic and molecular changes observed in these tumors. The WHO 
classification organizes brain tumors into neuroepithelial tumors of peripheral nerves, 
tumors of the meninges, lymphomas and hematological malignancies, germ cell tumors and 
metastatic tumors of the sellar region, with a total of over 100 distinct histological entities 
(Louis et al. 2007; Kleihues et al., 2002). 
CNS tumors that originate from neuroepithelial tissue, generically called gliomas, are the 
CNS neoplasms that are most frequently encountered in children and adults. The subtypes 
have different biological behaviors and are distinguished by their histological 
characteristics, such as nuclear atypia, mitotic index, blood microvessel formation and 
necrosis. Such peculiarities are also used to assess the degree of malignancy according to the 
standards adopted by the WHO (Louis, 2006;  Kleihues et al., 2002). Table 2 shows the WHO 
classification for neuroepithelial tumors in simplified form. 
 
Neuroepithelial tumors 
Astrocytic tumors  
Pilocytic astrocytoma  9421/1* 
Diffuse astrocytoma  9420/3 
Anaplastic astrocytoma  9401/3 
Glioblastoma  
 
Gliomatosis cerebri                                                                          
9440/3 
 
9381/3 
Oligodendroglial tumors  
Oligodendroglioma 9450/3 
Anaplastic  oligodendroglioma   
9382/3 
Ependymal tumors  
Ependymoma   
9391/3 
 
Anaplastic ependymoma  9392/3 
Myxopapillary ependymoma 9394/1 
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Neuroepithelial tumors 
 
Subependymoma                                                                               
 
9383/1 
Choroid plexus tumors  
Choroid plexus papilloma 
 
Atypical choroid plexus papilloma 
 
Choroid plexus carcinoma 
9390/0 
 
9390/1 
 
9390/3 
Mixed gliomas of uncertain origin  
 
Astroblastoma 
 
9430/3 
Angiocentric glioma 9431/1 
Chordoid gliomas of the third ventricle 9444/1 
Neuronal and mixed neuronal-glial tumors  
Ganglioglioma  
 
Anaplastic ganglioglioma 
9505/1 
 
9505/3 
Central neurocytoma  9506/1 
Embryonal tumors  
Medulloblastoma  9470/3 
Medulloepithelioma 
 
9501/3 
Atypical teratoid/rhabdoid tumor 9508/3 
Table 2. WHO classification for neuroepithelial tumors. * International Classification of 
Diseases - Oncology (ICD-O) (adapted from Louis et al., 2007). 
1.1 Astrocytic tumors 
The astrocytic tumors are derived from astrocytes, the principal glial support cells. These 
tumors are the most common primary brain tumors. They present extensive heterogeneity, 
differing in the location, age, extent, invasive potential, clinical course and tendency to 
progress (Khatua et al., 2003; Wang et al., 2003). Classically, astrocytomas are divided 
according to the degree of malignancy: pilocytic astrocytoma (Grade I), fibrillar diffuse 
astrocytoma (Grade II), anaplastic astrocytoma (Grade III) and glioblastoma multiforme 
(Grade IV). 
The pilocytic astrocytomas are rare neoplasms, with an estimated incidence of less than 1 
case per 100.000 person-years. They are predominantly pediatric tumors and are usually 
located in the cerebral hemispheres, with no infiltrative and circumscribed lesions. They are 
www.intechopen.com
The Role of Matrix Metalloproteinases and 
Tissue Inhibitors of Metalloproteinases in the Progression of Astrocytomas 597 
slow-growing and rarely lead to malignant transformation. Thus, these diffuse astrocytoma 
tumors are considered to be low-grade malignant neoplasms (Evren-Keles, et al., 2004). 
Although these neoplasms display benign behavior when located in the cerebral 
hemispheres, the same cannot be said when the lesions occur in the visual pathways or 
hypothalamus. 
Histologically, pilocytic astrocytomas are presented as tumors of low to moderate 
cellularity. They consist of astrocytes with regular, uniform nuclei and little atypia. They are 
characterized by the presence of numerous Rosenthal fibers, which are protein inclusions 
within their astrocytic prolongations (Strother et al., 2000). Surgery is the recommended 
treatment for these lesions and is curative in most cases. 
Chemotherapy has been used in specific cases, especially in children, with tumors of the 
optic tracts who experience progression after an initial period of observation and potential 
deterioration of vision (Packer et al., 1997). 
Diffuse or fibrillary astrocytomas (Grade II) are less frequent in children, and commonly 
affecting young adults. Histologically, these tumors have increased cellularity, often do not 
exhibit microcysts or Rosenthal fibers, tend to undergo anaplastic transformation more 
frequently and they are more infiltrative (Behin et al., 2003). 
Anaplastic astrocytomas (Grade III) are infiltrative, have a high proliferative potential and 
affect mainly adults. This type of tumor is associated with a shorter survival time than the 
two previously mentioned; presenting the three- or four-year survival in 70% of the cases. 
Surgery remains the best treatment option and this should target as wide an area as possible 
(Behin et al., 2003). 
Grade IV astrocytoma, more commonly called glioblastoma multiforme, is most frequent in 
adults and is the most aggressive tumor of this lineage; it corresponds to approximately 50% 
of the malignant tumors of the CNS. It is clinically aggressive, highly invasive and capable 
of invading extra-axially. This neoplasm often appears in adulthood, after 40 years of age, 
which does not mean it is  exclusive to this age group (Binder et al., 2003). 
The histological features of glioblastoma multiforme are hypercellularity, cellular atypia and 
anaplasia, frequent nuclear mitotic figures, necrosis and endothelial proliferation. (Behin et 
al., 2003; Strother et al., 2000). 
The optimal treatment is surgery, but many patients with neurological problems, the very 
elderly (over 80 years), and those at high risk of complications from anesthesia should be 
carefully evaluated; in many cases, biopsy is most suitable. Local radiotherapy is also 
indicated, even in cases where there is no indication for surgery. 
Glioblastomas may arise from the transformation of low-grade or anaplastic tumors (in 
which case they are called secondary glioblastomas), or they can be primary (in which case 
they are called primary glioblastomas) (Kleihues et al., 2000). Although this classification is 
widely accepted in clinical practice, the designation of primary or secondary glioblastomas 
is more conceptual than diagnostic and has no pratical impact on treatment. The molecular 
analysis of these tumors has led to a classification based on the genetic alterations 
commonly found in them, which can distinguish primary from secondary glioblastomas 
(Figure 1) (Kleihues & Ohgaki, 2007). 
2. The Extracellular Matrix (ECM) 
The ECM consists of a complex network of proteins and proteoglycans, secreted by the 
connective tissue, whose purpose is to support the tissues that make up an organism. This 
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network of proteins has a decisive influence on various biological activities (Giancotti et al. 
1999; Matrisian, 1990). 
The degradation of the ECM is a physiological process that is strictly controlled by the 
dynamic equilibrium between the activity of matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs). The cell–ECM interactions send signals promoting 
cell differentiation, migration and mobility that are necessary for cell homeostasis (Chang & 
Werb, 2001). MMPs degrade the ECM proteins and pericellular microenvironment, 
activating growth factors and adhesion molecules. These events are essential for a variety of 
physiological processes, such as embryonic development, remodeling, tissue repair and 
angiogenesis (Chakraborti et al. 2003; Löffek et al. 2010; Matrisian, 1990). 
The disordered destruction of the ECM plays a crucial role in the development of various 
pathologies, such as liver fibrosis, aneurysms, periodontosis, rheumatoid arthritis, multiple 
sclerosis, cystic fibrosis and tumor formation. The development of tumors is highly 
dependent on the microenvironment because the production and/or uncontrolled activation 
of proteolytic enzymes involved in the degradation and remodeling of the ECM are the 
determining factors in tumor development (Overall et al., 2002; Pollet et al. 2004). 
 
 
 
 
Fig. 1. The genetic pathways involved in the development of primary and secondary 
glioblastomas (adapted from Ohgaki & Kleihues, 2007).  
www.intechopen.com
The Role of Matrix Metalloproteinases and 
Tissue Inhibitors of Metalloproteinases in the Progression of Astrocytomas 599 
2.1 Matrix metalloproteinases  
The metalloproteinases are divided according to their biochemical characteristics as follows: 
MMPs; a disintegrin and metalloproteinases (ADAMs); and ADAMs with thrombospondin 
domains (ADAMS-TS) (Malemud, 2006; Werb, 1997). 
MMPs are zinc-dependent (Zn+2) peptidases with highly conserved substrate specificity that 
are capable of degrading proteoglycans, laminin, fibronectin, gelatin and fibrillar collagen 
(Types I, II, III, V and XI) on the basal membrane and in the ECM (Curran & Murray, 2000, 
Yong et al., 1998). There are more than 20 known members of this family of proteases. 
Mammalian MMPs are classified into soluble (secreted) and membrane (MT-MMPs) 
(Amalinei et al. 2007; Pei et al. 2000; Seiki, 1999). 
Soluble MMPs are synthesized as pro-enzymes, while the MT-MMPs are activated in the 
intracellular space and expressed on the cell surface as active enzymes. These MMPs are 
divided into four subclasses according to their structural and functional characteristics: 
collagenases, gelatinases, stromelysins, and matrilysins (Nabeshima et al., 2002; Nagase & 
Woessner, 1999; Visse & Nagase, 2003).  
The degradation of ECM is a physiological process that is strictly controlled by the dynamic 
equilibrium between the activity of matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinases (TIMPs). The cell–ECM interactions send signals that promote cell 
differentiation, migration and mobility, which are necessary for cell homeostasis (Chang & 
Werb, 2001). MMPs degrade ECM proteins and the pericellular microenvironment, 
activating growth factors and adhesion molecules. These events are essential for a variety of 
physiological processes, such as embryonic development, remodeling, tissue repair and 
angiogenesis (Chakraborti et al. 2003; Löffek et al. 2010; Matrisian, 1990). 
The general structure of MMPs consists of three domains that are highly conserved among 
this family but still distinct: a pro-N-terminal domain, a catalytic domain, and a C-terminal 
domain that contains the conserved hemopexin (HEXGHXXGXXH) motif (the matrilysins 
subfamilies do not have this motif). The histidine residues (H) contained in the hemopexin 
domain are involved in binding to Zn+2, which is required for its proteolytic activity. The 
pro-domain of MMPs also contains a highly conserved PRCGVDP motif that bonds 
covalently to Zn+2, keeping the protein in its non-activated zymogen form. Gelatinases have 
a binding site for fibronectin in the catalytic domain that confers specificity to the substrate 
(Figure 2) (Nakada et al. 1999; Pollet et al. 2004; Vihinen & Kalahari, 2002). 
The collagenase subfamily includes MMP-1, MMP-8, MMP-13 and MMP-18, which exhibit 
biochemical characteristics that allow them to cleave interstitial collagen I, II and III in a site-
specific N-terminal domain. Interstitial collagen I is one of the most abundant substances in 
the human body, so collagenases play an important role in the process of remodeling and 
degrading the ECM (Curran & Murray, 2000; Visse & Nagase, 2003). 
The gelatinases include gelatinase A (MMP-2) and gelatinase B (MMP-9). These enzymes are 
specialized in degrading Type IV collagen, the main constituent of the basement membrane 
of cerebral blood vessels. As previously mentioned, these enzymes have three repeats of a 
fibronectin domain in their catalytic domains, which allows the gelatinases to bind to 
laminins and gelatin (Yong et al., 1998). 
MMP-2, is a 72-kDa gelatinase, encoded on human chromosome 16q13 and constitutively 
expressed in variety of  cell types. This enzyme has the ability to degrade collagen V, VII, XI 
and fibronectin. MMP-2 also mediates proliferation, adhesion and cell migration. This 
enzyme is secreted in its inactive form and gains catalytic activity by interacting with the 
complex formed by membrane metalloproteinase 1 (MT1-MMP, or MMP-14) and TIMP-2 
(Chintala et al., 1999). 
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Fig. 2. The general structure of MMPs and their subfamilies (Vihinen & Kalahari, 2002). 
MMP-9 is a 90–110-kDa protein encoded in the region 20q11.2-13.1. This enzyme is also 
secreted as a zymogen that can be stored in an active or latent form in the cytosol. The 
expression of MMP-9 is not constitutive and may be influenced by many factors, such as cell 
growth, cytokine signaling, cell–cell adhesion and cell–ECM interactions. The mechanism of 
protease activation thus involves a complex web of interactions with other MMPs and 
TIMPs (Amalinei et al. 2007; Chintala et al. 1999). 
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The stromelysins group is composed of the following proteases: MMP-3 (stromelysin-1), 
MMP-10 (stromelysin-2); and MMP-11 (stromelysis-3). These proteases have similar 
substrates, but MMP-3 has higher proteolytic activity than the other stromelysins. MMP-3 is 
expressed in several cell types and acts on the following ECM components: collagen, gelatin, 
elastin, fibronectin, and vitronectin. In addition to digesting the ECM components, MMP-3 
participates in the activation of pro-MMP-1 and pro-MMP-9 (Egeblad & Werb, 2002). 
The membrane-MMP subfamily consists of six MT-MMPs (MT1-MMP through MT6-MMP) 
and two glycosylphosphatidylinositol (GPI)-anchored MMPs (MMP-17 and MMP-25). One 
of the most prominent members of this subfamily is MT1-MMP (MMP-14), whose substrates 
are collagen Types I, II and III, gelatin, fibronectin and laminin (Koshikawa et al., 2000). 
MT1-MMP is considered a multifunctional molecule. It is directly involved in cell growth, 
inflammation, the formation of new vessels, and the processes of cell adhesion and 
migration. Consequently, it plays a role in the formation of metastases (Shiomi & Okada, 
2003; Yana & Seiki, 2002). 
Its interactions with MT1-MMP cause TIMP-2 to play a crucial role in the activation of pro-
MMP-2. The catalytic domain of MT1-MMP binds to the N-terminal domain of TIMP-2, 
causing the C-terminal region of TIMP-2 to become capable of connecting to the hemopexin 
domain of pro-MMP-2. The location of this protease in the membrane plays a role in 
pericellular proteolysis because this molecule activates pro-MMP-2, enabling it to use 
exogenous substrates to mediate the processes of invasion and metastasis. (Sternlicht & 
Werb, 2001; Sounni et al., 2003). 
The expressions of MMPs are under the control of a sophisticated genetic mechanism. 
Under basal circumstances, levels of MMPs are relatively low; however, the expression of 
MMPs is increased by the processes of ECM remodeling that result from physiological or 
pathological conditions. The expression of some subfamilies of MMPs is tissue-specific. The 
regulation of the expressions of MMPs occurs by three main routes:  transcriptional 
regulation of MMPs; activation of pro-enzymes, and inhibition by the action of TIMPs 
(Nagase et al., 2006; Yong et al. 1998). 
2.1.1 Transcriptional regulation of MMP genes 
The transcription factors that regulate MMP gene expression include activating protein-1 
(AP-1), polyoma enhancer activator 3 (PEA3), SP1, ǃ-catenin/Tcf-4 and NF-κB, these factors 
seem to have synergistic effects on MMP gene regulation. Based on the composition of their 
regulatory elements, the promoters of these genes can be divided into Classes I, II and III 
(Yan & Bold, 2007). 
The Class I promoters contain a TATA box at position -30 (relative to the transcription start 
site) and an AP1-binding site at position -70. Many of these promoters also contain a binding 
site for PEA3 that is adjacent to the AP1 site. The Class II promoters also have a TATA box 
but without the proximal AP1 site. The regulation of these promoters is relatively simple 
and it is distinct from the regulation of the Class I promoters (Benbow & Brinckerhoff, 1997; 
Chakraborti et al., 2003). 
The third and final group of promoters does not have a TATA box, meaning that 
transcription begins at multiple sites. However, the SP1 family of transcription factors, 
which bind close to the GC box, . controls the regulation of this group. The FOS and JUN 
proteins actively participate in the transcription regulatory mechanism by forming a 
heterodimer that binds to the AP1 sites and stimulates the transcription of MMPs in 
response to inflammatory cytokines (Matrisian, 1990). The structural differences between 
the MMP promoters are shown in Figure 3. 
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Fig. 3. The types and structures of the MMP-gene promoters (adapted from Yan & Bold, 
2007). 
2.1.2 Activation of proenzymes 
MMPs are synthesized as zymogens. These enzymes can be activated by proteases in vivo or 
in vitro after exposure to chemical agents, such as thiol compounds (HgCl2 and N-
ethylmaleimide), SDS, reactive oxygen species, and exposure to heat or acidic pH. 
Activation in vivo occurs in the extracellular space and requires breaking the zinc–cysteine 
complex to expose its catalytic site. The cysteine residue (C) of the PRCGVPD sequence in 
the pro-domain interacts with the catalytic portion of the Zn2+ while maintaining the pro-
MMPs in latent form. The disruption of this C–Zn2+ interaction results in a partial activation 
of the intermediate form of the enzyme, leading to the autocatalysis of the pro-peptide 
region that provides full activity to the enzyme. This mechanism allows the pro-MMPs to be 
activated by multiple agents, as mentioned above (Ra & Parks, 2007; Van Wart & Birkedal-
Hansen, 1990). 
The plasminogen/urokinase system is also an important physiological activator of pro-
MMPs. The plasminogen activator of urokinase is associated with the membrane, thus 
creating an activation site for pro-MMPs and the subsequent renewal of the ECM. Plasmin 
can activate pro-MMP-1, pro-MMP-3, pro-MMP-7, pro-MMP-9, pro-MMP-10 and pro-MMP-
13 (Nagase et al., 2006). 
Most pro-MMPs that are secreted into the extracellular space are activated. Some pro-MMPs 
have a furin domain (KCKR) that allows them to be activated by furin in the intracellular 
space. These pro-enzymes include pro-MMP-11, MT-MMPs, pro-MMP-23 and pro-MMP-28 
(Amalinei et al., 2007; Satmenkovic, 2003). 
The activation of pro-MMP-2 is mediated by the MT-MMPs, with the exception of MT4-
MMP, and it depends on the participation of TIMP-2. Pro-MMP-2 forms a complex with 
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TIMP-2 through its C-terminal domain, allowing the N-terminal domain of TIMP-2 to bind 
to MT1-MMP on the cell surface. The complex containing MT1-MMP, TIMP-2, and pro-
MMP-2 is then presented to an adjacent free MT1-MMP, which activates the pro-MMP-2. 
The hemopexin domain seems to facilitate this activation process (Jo et al., 2000). 
2.2 Tissue inhibitors of metalloproteinases 
The TIMPs constitute the third regulatory level of MMP expression. These proteins are 
major physiological inhibitors of MMPs. The TIMPs are low-molecular-weight, 21–30 kDa, 
molecules that have approximately 12 cysteine residues that are involved in disulfide 
bridges, six of which are responsible for the formation of two domains that are essential for 
the interaction of these molecules with MMPs. The C-terminal domain is responsible for the 
interaction with and activation of pro-MMPs and for the subcellular localization of these 
proteins. The N-terminal domain acts as an independent unit that inhibits the activity of 
MMPs (Baker et al., 2002; Brew et al. 2000). 
Blocking the proteolytic activity of both soluble and membrane-bound MMPs is 
accomplished by TIMPs through the formation of monocovalent complexes at a 1:1 ratio 
between the catalytic site of MMPs and the N-terminus of TIMPs. The amino groups and 
carbonyl groups of the cysteine residues in the N-terminus of TIMPs act together to chelate 
the Zn2+ in the catalytic domain of MMPs, making Zn2+ unavailable to activate the MMPs 
(Nagase et al., 2006; Visse & Nagase, 2003). 
Four TIMPs, designated as TIMP-1 through TIMP-4, have been characterized in humans. 
They are resistant to heat denaturation and proteolytic degradation. These proteins are 
expressed in a variety of cell types and fluids (Gómez et al., 1997). Although all TIMPs are 
capable of inhibiting all the MMPs that have been studied, they differ in many aspects, such 
as solubility, the complementary nature of the pro-enzymes and the regulation of 
expression. TIMP-1, TIMP-2 and TIMP-4 are present in the soluble form, while TIMP-3 is 
connected to the ECM (Lamfers et al., 2005). The expression of TIMP-1 is inducible. This 
molecule has weak inhibitory action against MMP-19 and MT-MMPs (MT-MMP1, MT-
MMP-2, MT-MMP-3 and MT-MMP-5) and even inhibits ADAM -10. The expression of 
TIMP-2 is constitutive, and it has strong inhibitory action against the MT-MMPs. TIMP-3 
may also inhibit other members of the ADAM family, such as ADAM-17, ADAMTS-4 and 
ADAMTS-5, and the inhibitory effects of this molecule on MMP-9 are greater than those 
observed for TIMP-1 and TIMP-2. TIMP-4 expression is inducible, and it appears to inhibit 
the activities of MMPs constitutively. Table 3 presents some of the molecular characteristics 
and biological properties of TIMPs. 
The TIMPs have also the ability to form complexes with pro-MMPs, thus regulating their 
activation. TIMP-1 preferentially forms complexes with pro-MMP-9, and TIMP-2 binds 
preferentially to pro-MMP-2 to facilitate its activation (Baker et al., 2002). TIMP-3 binds to 
both pro-MMP-2 and pro-MMP-9 (Bigg et al., 1997), and TIMP-4 can bind to the C-terminal 
domain of pro-MMP-2 (Butler et al., 1999). 
The inhibition of MMPs is not unique to TIMPs. Molecules such as ǂ-macroglobulin, general 
protease inhibitors, ǃ-amyloid precursors linked to the cell membrane, and the membrane 
protein RECK play the same. RECK is a GPI-type, membrane-anchored protein that 
decreases the catalytic activity of MMP-2, MMP-9 and MT1-MMP and can overcome the 
angiogenic activity in neoplastic processes, leading to the death of tumor cells (Oh et al., 
2001). A scheme for the interaction between the activation and inhibition of MMPs by TIMPs 
is presented in Figure 4. 
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 TIMP-1 TIMP-2 TIMP-3 TIMP-4 
Chromosomal 
location 
Xp11.23-11.4 17q23-17q25 22q12.1-
22q13.2 
3p25 
mRNA (kb) 0,9 3,5 5,0 1,4 
Molecular weight 
(kDa) 
28,5 21 22/27 22 
Protein localization Soluble Soluble ECM Soluble 
Associated pro-MMPs pro-MMP9 pro-MMP2 pro-MMP2/9 pro-MMP2 
Gene Expression Induced Constitutive Induced Induced 
Tumorigenic effects Inhibition Inhibition Inhibition Inhibition 
Metastases Stimulates ____ ____ Stimulates 
Table 3. The molecular and biological characteristics of TIMPs (adapted from Baker et al., 
2002). 
 
 
 
Fig. 4. MMPs are a class of proteases secreted by tumor cells. RECK is a membrane-anchored 
inhibitor of MMPs. It inhibits MMP-2, MMP-9 and MT1-MMP. Soluble, secreted MMP 
inhibitors, TIMPs, have also been identified. They appear to be less active at inhibiting 
MMPs and are perhaps even essential for MMP maturation. The inhibition of MMPs by 
RECK inhibits invasion of tissues, metastasis and tumor angiogenesis and is essential for 
normal development. (www.biocarta.com). 
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The main function of TIMPs is to act as natural receptor inhibitors of metalloproteinases. 
However, some studies have attributed other functions to TIMPs. Some of these functions 
are related to inhibiting MMPs and others are independent of it, such as promoting cell 
proliferation, anti-apoptosis activity and anti-angiogenesis (Chang & Werb, 2001; Chirco et 
al., 2006). 
The induction of cell proliferation by TIMPs was first described for TIMP-1 and TIMP-2; 
they enhance the effect of erythropoietin in the proliferation and differentiation of erythroid 
progenitors. This property was observed not only in this cell type but also in keratinocytes, 
chondrocytes, epithelial cells and cancer cells (Hayakawa et al. 1992; Murat et al., 1993). In 
addition to promoting cell proliferation, the TIMPs may also modulate apoptosis in various 
ways, including opposing effects. TIMP-1 and TIMP-2 are involved in resistance to 
apoptosis in normal and cancer cells. The effect of TIMP-3 is different because it promotes 
apoptosis in smooth muscle cells, inducing the shedding of the ECM from transformed cells 
(Baker et al., 1998). 
The effects of TIMP-4 in modulating apoptosis are contradictory; fibroblast-transformed 
heart tissue appear to be induced to apoptosis by TIMP-4, and the protein seems to have an 
inhibiting effect on apoptosis when hyperexpressed in breast-tumor cell lines (Baker et al., 
2002). 
Angiogenesis is described as the biological process of new capillary formation from existing 
vessels, which occurs in normal and pathological events. The TIMPs have anti-angiogenic 
activity, as was first demonstrated for TIMP-1 and TIMP-2. When hyperexpressed, they 
reduce angiogenic activity in pancreatic adenocarcinomas (Bloomston et al., 2002). TIMP-3 
also has anti-angiogenesis and anti-invasion activities. For example, it reduces the 
invasiveness of the HT1080 cell line derived from fibrosarcoma and the expression of MMP-
9, a molecule with known angiogenic activity (Lamfers et al., 2005). These observations 
corroborate the notion that the imbalance between the expressions of MMPs and TIMPs has 
a decisive role in the initiation and development of neoplastic processes. 
2.3 The role of MMPs in progression of astrocytic tumors 
Since the discovery of MMPs in 1962 by Gross and LaPierre, these enzymes have attracted 
great interest among researchers for their involvement in various physiological and 
pathological events. However, only in the 1980s, MMPs were discovered to be involved in 
the development and progression of tumors, a function that is widely studied to this day 
(Bourboulia & Stetler-Stevenson, 2010; Matrisian  et al., 1986). 
The invasive properties of CNS tumors are of great clinical importance because they 
contribute to the aggressive behavior of these tumors (Rao, 2003). For reasons still not well 
clarified yet , most primary neuroepithelial tumors do not evolve into metastatic disease. 
However, these tumors invade surrounding tissues, infiltrate their cells into normal tissue 
and (more rarely) spread along the neuro-axis into the cerebrospinal fluid. 
The mechanism of astrocytic-tumor invasion is a complex process in which tumor cells 
separate from the parental tumor and rejoin the ECM. This process is associated with an 
increase in cell motility and with the ability of tumor cells to hydrolyze proteins, 
carbohydrates and proteoglycans in the ECM. These cells perform this task through the 
excessive production of proteases that modify the ECM, thus creating access to the 
surrounding tissues and promoting migration to other parts of the brain (Levicar et al., 
2003). 
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MMPs are among the proteases that can degrade the ECM in brain tissue. The integrity of 
the ECM depends on a dynamic balance between MMP and TIMP activities. The loss of this 
balance can lead to the creation of a permissive environment for the initiation and 
development of a neoplastic process in brain tissue. MMPs, TIMPs and cell adhesion 
molecules are involved in the development of CNS malignancies (Forsyth et al. 1999; 
Mohana et al. 1995; Nakada et al. 2001; Rooprai et al., 1998). Changes in the expression of 
these proteins appear to be directly linked to the invasiveness of tumor cells. Classically, 
MMPs are considered to be responsible for promoting tumor growth, while TIMPs are 
thought to block the invasive ability of tumors (Amalinei et al. 2010; Deryugina & Quinley, 
2006). 
High-grade astrocytomas and medulloblastomas are neuroepithelial tumors of different 
cellular origins and are highly invasive. The degradation of the ECM is a prerequisite for 
invasion by these tumors. Among the MMPs that are commonly associated with the 
progression of astrocytic tumors are the gelatinases and the membrane MMPs, especially 
MT1-MMP1. Gelatinases A (MMP-2) and B (MMP-9) are undoubtedly the most well-studied 
MMPs in CNS tumors, and they have been identified as important factors in the 
development of high-grade gliomas (Munaut et al. 2003; Pagenstecher et al. 2001; Zhao, et 
al., 2007). This observation is directly linked to the invasive nature of these tumors because 
the expression levels of these gelatinases are generally low in normal brain tissue (Van 
Meter et al., 2001). 
A study by Jäälinojä et al. (2000) demonstrated that the high expression of MMP-2 is a 
characteristic of highly malignant tumors and is associated with poor patient survival,  
similar data were also observed by Kunishio et al. (2003), who used immunohistochemistry 
analysis to show that MMP-2 and MMP-9 are not associated with increased aggressiveness 
in astrocytic tumors. 
Komatsu et al. (2004) studied the expression of MMP-2 and MMP-9 in human gliomas by 
using two different techniques, RQ-PCR and immunohistochemistry, the results revealed no 
correlation between the expression of MMP-2 protein and the degree of malignancy. 
However, quantitative analysis of the mRNA showed that tumors of the highest grade, such 
as glioblastomas, express much higher levels of the MMP-2 and MMP-9 genes than do low-
grade tumors. This study clearly demonstrated that methodological differences may explain 
some of the conflicting results found in the literature. 
Increased levels of MMP-2 and MMP-9 and their relationships with astrocytic tumors of 
greater aggressiveness and invasiveness have also been reported by a number of authors, 
such as Forsyth et al. (1999), Lampert et al. (1998), Munaut et al. (2003), Pagenstecher et al. 
(2001) and Wang et al. (2003). Wild-Bode et al. (2001) reported that the overexpression of 
MMP-2 and MMP-9 is the best predictor of cell invasion by high-grade gliomas.  
Another important result that highlights the prognostic significance of elevated MMP-9 
expression was discovered by Hormigo et al. (2006), who found elevated MMP-9 protein in 
the serum of patients suffering from high-grade astrocytomas, which was not observed in 
low-grade tumors or in non-neoplastic tissue. These authors also suggested that MMP-9 can 
be used as a biomarker in the management of glioblastoma patients. 
The analysis of MMP-9  expression conducted by our group revealed that this gene is 
expressed more highly in astrocytic tumors than in non-tumor tissue. The expression is 
much greater in tumors with the highest degree of malignancy, especially glioblastomas, 
than in low-grade astrocytomas. Our study also revealed that pilocytic astrocytomas arising 
in the optic tracts, hypothalamus and pituitary gland, which appear to exhibit more 
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aggressive behavior, show higher expressions of MMP-9 than do the tumors that originate 
in the cerebral hemispheres (unpublished data). These observations suggest that 
overexpression of MMP-9 is one of the main mechanisms necessary to increase the 
invasiveness and aggressiveness of CNS tumors. Our data also show that overexpression of 
MMP-9 in patients suffering from glioblastomas is significantly associated with decreased 
overall survival, as shown in Figure 5 (unpublished data). A multivariate analysis suggested 
that overexpression of MMP-9 is an independent prognostic factor of paramount 
importance in the management of glioblastoma patients. These observations support the 
hypothesis that abnormal expression of MMP-9 is a determinant of aggressiveness in 
astrocytic tumors. 
 
 
Fig. 5. The Overall survival of glioblastoma patients. The patients who overexpress the 
MMP-9 gene have significantly lower survival than patients with no marked upregulation 
of this gene (unpublished data). 
Our observations suggest that overexpression of MMP-9 increases the invasiveness of 
astrocytic tumors, making it a potential target for combating these neoplasms. Other 
authors, such as Vince et al. (2001), have found higher levels of expression of this gelatinase 
in medulloblastomas than in glioblastomas. They also observed that MMP-2 is more 
commonly found in areas of intense proliferative activity, while MMP-9 is associated with 
sites of angiogenesis, a typical feature of the invasive capacity of these tumors. Angiogenesis 
is highly dependent on the migration and invasion of endothelial cells into tissues. The ECM 
sequesters and stores angiogenesis-promoting factors, such as VEGF, bFGF and TGF1, 
which are released during the proteolytic degradation of the ECM. Accordingly, MMPs play 
a critical role in the process of angiogenesis. MMPs both promote and inhibit angiogenesis 
(Jain et al. 2007; Rundhaug, 2005; Zhao et al., 2008). 
Gelatinases are the main promoters of the invasion of endothelial cells in the CNS (Lakka et 
al., 2005). MMP-2 is constitutively expressed by endothelial cells and interacts with 
thrombin, which is present at high levels in angiogenic sites. This interaction leads to 
activation of protein C on the surface of the endothelium. Activated protein C interacts with 
P=0,007
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latent MMP-2 to increase its protease activity, thus allowing the endothelial cells to degrade 
the basement membrane. MMP-9 is then activated by intracellular vesicles secreted from 
endothelial cells to enhance the degradation of basement membrane. When the basement 
membrane reaches the interstice, the abundant collagen Type I contributes to the prolonged 
activation of MMP-2, thus consolidating the process of angiogenesis (Nguyen et al., 2001). 
Glioblastomas are astrocytic tumors with increased invasive behavior, this property is 
closely related to their high vascularization. In vivo and in vitro, MMP-2 and MMP-9 are 
hyperexpressed in endothelial cells of glioblastomas (Vince et al., 2001; Zhao et al., 2010). 
The direct involvement of these proteins in angiogenesis may explain our observation of 
increased expression of MMP-2 and MMP-9 mRNA in highly malignant tumors 
(unpublished data). Similar results were found by Munaut et al. (2003), who also observed 
that overexpression of MMP-2 and MMP-9 is correlated with overexpression of VEGF in 
glioblastomas, a key mediator of angiogenesis.  
Elevated expression of MMP-2 and MMP-9 and its clinical and biological implications for 
other cancers have been reported in several studies. Cho et al. (2007) reported that 
overexpression of MMP-9 is associated with poor prognosis in colorectal tumors. Similar 
observations were obtained by Kawata et al. (2007) for renal tumors and Iniesta et al. (2007) 
for non–small cell lung cancer. 
Like the gelatinases, MT1-MMP is considered to be a promoter of tumor cell invasion and a 
facilitator of metastasis. MT1-MMP promotes the acquisition of invasive capacity in both 
normal and neoplastic cells through its ability to degrade pericellular collagen. It also 
facilitates angiogenesis by activating endothelial cells. This activity has been documented 
both in vivo and in vitro (Martin & Matrisian, 2007). The pro-invasive activity of MT1-MMP 
has been associated by some authors with invasion and progression in other tumors, such as 
neck tumors by Zhai et al. (2005) and astrocytic tumors by Forsyth et al. (1999); Nakada et al. 
(1999, 2001) and Kong et al. (2007). 
Among the studies that have found a direct relationship between the increased expression 
of MT1-MMP and the evolution of gliomas, that of Nuttall et al. (2003) stands out because it 
found a greater than 21-fold increase in the level of MT1-MMP mRNA in glioblastomas 
relative to non-tumor brain tissue. The overexpression of MT1-MMP was also reported in a 
glioblastoma cell line (U251), the most invasive of the strains tested by the authors. This 
increase in the level of MT1-MMP was accompanied by the overexpression of MMP-2 and 
MMP-9 and of genes related to angiogenesis, such as VEGF. Munaut et al. (2003) also 
reported that strong expression of VEGF is accompanied by overexpression of MMP-2, 
MMP-9 and MT1-MMP and that these proteins act synergistically to create a permissive 
environment for glioblastoma cell invasion. Pagenstecher et al. (1999) also observed that the 
levels of MMP expression in pilocytic astrocytomas are comparable to those observed in 
anaplastic astrocytomas and glioblastomas, suggesting that this molecule is a major player 
in the progression of astrocytic tumors.  
Arroyo et al. (2007) and Basile et al. (2007) demonstrated that MT1-MMP plays a crucial role 
in angiogenesis and that this protein is usually hyperexpressed at sites of neoangiogenesis. 
We believe that our observations are related to the level of vascularization of these tumors, 
and high-grade pilocytic astrocytomas have a significant level of vascularization. The 
overexpression of MT1-MMP and its relationship with the aggressive behavior of tumors 
have also been described in soft tissue cancers Roebuck et al. (2005) and more recently by 
Sroka et al. (2008) in prostate tumors. 
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2.4 The role of TIMPs in the progression of astrocytic tumors. 
A high level of TIMP expression may occur in two distinct contexts: (1) as part of the 
defense mechanisms of the host tissue against the invasion; and (2) as promoter, either 
directly or indirectly, of cell growth in the tumor mass that helps the tumor progress and 
invade adjacent structures (Brand, 2002). The latter property directly promotes the evolution 
of these lesions to higher-malignancy tumors.  
TIMP-1 is involved in a series of biological and pathological processes, including growth-
promoting activity, inhibition of angiogenesis and changes in cell morphology. In the CNS, 
this molecule seems to possess the neuroprotective effect of maintaining the blood–brain 
barrier by its inherent inhibitory action on MMPs. TIMP-1 also has the distinguishing 
characteristic of not being able to inhibit MT1-MMP, in contrast to other TIMPs (Duffy et al., 
2008). TIMP-1 is also involved in the development of neuroepithelial tumors (Gardner & 
Ghorpade, 2003; Lampert et al. 1998; Kakagawa et al. 1994; Pagentecher et al. 1999). Groft et 
al. (2001) showed that overexpression of TIMP-1 is associated with malignancy in gliomas 
and that TIMP-1 is detected mainly near the sites of blood vessel formation. These 
observations could be a result of interactions with pro-MMP-9 and the angiogenesis-
promoting ability of this MMP. Huang et al (2005) and Pagentecher et al. (1999) found 
higher levels of TIMP-1 expression in pilocytic astrocytomas and glioblastomas. This result 
seems contradictory, but it may act to offset the simultaneous increases in the expression of 
MMP-9 and TIMP-1 because TIMP-1 preferentially inhibits MMP-9. The results of 
Pagentecher et al. (1999) also showed that this overexpression is linked to sites of 
neoangiogenesis. 
Overexpression of TIMP-1 appears to be an important prognostic factor for patients with 
breast cancer, since those patients with greater expression of this gene have higher survival 
rates (Nakopoulou et al., 2003). However, we found no similar reports for astrocytic tumors. 
TIMP-2 preferentially inhibits MMP-2 and activates pro-MMP-2 by forming complexes with 
MT1-MMP. Béliveau et al. (1999), Huang et al. (2005) and Nakada et al. (2001) suggests that 
there is an inverse correlation between the expression of TIMP-2 and the degree of 
malignancy in CNS tumors. This result may be related to the antagonistic effects of these 
genes in the classical biological behavior of astrocytic tumors, in which MMPs act as 
promoters of invasion and TIMPs as blockers of tumor growth. Nuttal et al. (2003) has also 
detected high levels of TIMP-2 mRNA and protein expression in non-neoplastic brain-tissue 
samples. The in vitro protective effects of TIMP-2 were also described by Papi et al. (2007) in 
experiments using cells derived from gliomas. Moreover, Saxena et al. (1999) found a 
positive correlation between the expressions of TIMP-2 and MMP-2 and the degree of 
malignancy of CNS tumors, in which the highest levels of expression of these genes are 
primarily found in recurrent tumors. The increased expression of TIMP-2 in these tumors 
may be related to defense against invasion or, more precisely, to the attempt to block the 
proteolytic activity of MMP-2, which facilitates tumor invasion. Other associations between 
the expression of TIMP-2 and survival in patients affected by CNS tumors have not been 
found. Curran et al. (2004) observed that the loss of TIMP-2 expression contributes 
significantly to the low survival rate of patients suffering from colorectal tumors. 
The loss of TIMP-3 expression is related to cancer development, and normal brain tissue has 
high levels of TIMP-3. This physiological inhibitor of MMPs antagonizes the activity of most 
metalloproteinases, thereby leading to the inhibition of tumor growth, angiogenesis, 
invasion and metastasis formation. The overexpression of this gene in tumor cells seems to 
promote apoptosis and suppress early tumor growth (Hoe et al., 2007). 
www.intechopen.com
 
Molecular Targets of CNS Tumors 610 
A study using microarray analysis that was conducted by Bozinov et al. (2008) showed that 
TIMP-3 is one of the genes preferentially expressed in less-malignant CNS tumors. Huang et 
al. (2003) also observed that non-neoplastic tissue has low expression of TIMP-3. 
Furthermore, Lampert et al. (1998) and Pangestecher et al. (1999) found no variation in the 
gene expression levels between gliomas and suggested that this observation is consistent 
with constitutive expression. The protective effect of TIMPs against invasion by glioma cells 
was demonstrated by Lamfers et al. (2005), who used an adenovirus to transfer the gene for 
TIMP-3 into cultured cells, which resulted in increased expression of the gene and a 
reduction in the invasive capacity of the cells. The main cause of the decreased expression of 
TIMP-3 is the hypermethylation of its promoter region. Gonzalez-Gomez et al. (2003a, 
2003b) have shown that the promoter region of this gene is hypermethylated in 
glioblastomas, especially in secondary glioblastomas, and in medulloblastomas. Nakamura 
et al. (2005) have also found that the loss of heterozygosity in region 22q12.3, the region 
containing the TIMP- gene, is a frequent event in glioblastomas. These authors also 
suggested that these molecular alterations may be the primary cause of decreased 
expression of TIMP-3 in high-grade astrocytic tumors. Nakamura et al. (2005) have shown 
that hypermethylation of TIMP-3, and the consequent reduced expression of the gene, is an 
important factor in the poor survival of patients affected by highly malignant tumors. 
Correlations between decreased expression of this gene and low survival rates have also 
been observed in colorectal cancer (Hilska et al., 2007), non–small cell lung cancer (Mino et 
al., 2007) and bladder carcinomas (Hoque et al., 2008). 
TIMP-4 has been studied less than the other TIMPs. It was discovered by Greene et al. 
(1996), who identified an expressed sequence tag (EST) with that was closely related to that 
of other TIMPs. This EST was identified and cloned in cDNA libraries from the human 
heart. They identified low levels of this transcript in a variety of tissues and organs, such as 
kidney and placenta, and did not observe expression of the gene in tissues derived from 
brain, lung, thymus or liver. These authors suggested that the contribution of TIMP-4 to 
maintaining the homeostasis of the ECM is tissue-specific. Bigg et al. (1997) also showed that 
TIMP-4 has a strong affinity for pro-MMP-2 and that, together with TIMP-2, it participates 
in the activation of pro-gelatinase A. The literature addressing the involvement of TIMP-4 in 
the development and progression of CNS tumors is sparse. Groft et al. (2001) have identified 
an inverse relationship between the expression of TIMP-4 and malignant CNS tumors. 
Microarray data obtained by Rorive et al. (2006) also show that TIMP-4 is preferentially 
expressed in pilocytic astrocytomas relative to normal brain tissue, Grade II astrocytomas 
and high-grade astrocytomas (Grades III and IV).The elevated expression of TIMP-4 in 
samples with low invasive potential compared to more aggressive tumors is not unique to 
CNS tumors. Similar findings have also been observed in studies of cells derived from 
breast tumors (Wang et al., 1997), prostate tumors (Lee et al., 2006) and rectal tumors (Hilska 
et al., 2007), in which the authors also observed that patients with higher expressions of 
TIMP-4 showed increased survival. However, our data revealed no relationship between the 
expression of TIMP-4 and patient survival. These findings suggest that the supposed 
protection afforded by the overexpression of TIMP-4 is directly related to the ability of this 
molecule to promote the apoptosis of tumor cells (Guo et al., 2004). 
The inherent properties of TIMPs can be exploited to achieve therapeutic benefits in various 
diseases. The role of the MMP/TIMP balance in blocking or even reversing tumor 
progression has led to the development of synthetic inhibitors of MMPs (ISMPs). Clinical 
trials evaluating the ISMPs, like batimastat and marimastat for cancer treatment have shown 
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encouraging results, although they are less effective in advanced cancers and do have some 
side effects (Baker et al., 2002). 
However, the results observed in animal models have shown that the use of Chantix 
prevented tumor growth and vascularization of pre-malignant tumors (Bergers et al. 1999; 
Mucha et al., 2007). TIMP gene therapy has also emerged as an important therapy for certain 
cancers, such as prostate (Deng et al., 2008) and hepatocellular carcinoma (Xia et al., 2006). 
3. Conclusion 
Recent advances in genetics and molecular biology have provided a great leap in 
understanding the molecular events responsible for the development and progression of 
brain tumors. The assessment of the level of expression of genes involved in the creation and 
maintenance of tumors of the nervous system can provide accurate information as which 
genes are involved in the development of a specific type of CNS tumor and to determine the 
molecular pathways that may become targets for therapy. Thereby, improving the prognosis 
of patients affected by this neoplasia, and their chances of cure. In this scenario the 
imbalance in the expression of MMPs and TIMPs seems to be an important clue to  the 
progression, and therefore the aggressiveness, of astrocytic tumors. The invasive nature of 
these tumors is a major constraint on the efficacy of available therapies, especially for highly 
malignant astrocytomas. Therefore, a complete understanding of the interaction between the 
molecules that promote and block the migration routes of tumor cells will contribute 
significantly to developing new therapies to combat the progression of CNS tumors. 
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